Pernix Therapeutics Holdings Inc. (PTX) 7.44 $PTX
Pernix Therapeutics Holdings (PTX) Is Today's Dead Cat Bounce Stock
at The Street - Wed Apr 22, 8:49AM CDT
Trade-Ideas LLC identified Pernix Therapeutics Holdings (PTX) as a "dead cat bounce" (down big yesterday but up big today) candidate
PTX: 7.44 (-0.05)
A Look at the Health of the HealthCare Sector: Complementary Research on Horizon Pharma, Enzon Pharmaceuticals, Momenta Pharmaceuticals, Athersys, and Pernix Therapeutics
PR Newswire - Tue Apr 21, 9:46AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENZN: 1.70 (+0.20), PTX: 7.44 (-0.05), HZNP: 30.96 (+0.10), ATHX: 1.34 (+0.01), MNTA: 18.62 (+0.56)
FDA grants pediatric exclusivity for Pernix's Treximet; patents extended into 2018
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 9:24AM CDT
PTX: 7.44 (-0.05)
Pernix Therapeutics prices issue of USD130m convertible senior notes
M2 - Mon Apr 20, 8:17AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NYSE
TX) said on Friday that it has priced its private offering of USD130m aggregate principal amount of 4.25% convertible senior notes due 2021.
PTX: 7.44 (-0.05)
Pernix Therapeutics Inc. Obtains Six Months U.S. Pediatric Exclusivity for Treximet
Business Wire - Mon Apr 20, 6:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced that Pediatric Exclusivity has been granted by the U.S Food and Drug Administration (FDA) for studies conducted on Treximet(R) (sumatriptan/naproxen sodium), effective April 16, 2015, under section 505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a). Based on this decision, an additional six months of U.S. market exclusivity will attach to the patents that are listed in FDA's Orange Book for Treximet, or until February 14, 2018.
PTX: 7.44 (-0.05)
Pernix Therapeutics Inc. to Report First Quarter 2015 Financial Results
Business Wire - Fri Apr 17, 3:14PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, announced today that it will release its first quarter 2015 financial results on Friday, May 1, 2015, before the market opens.
PTX: 7.44 (-0.05)
Pernix prices upsized convertible debt offering
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 6:23AM CDT
PTX: 7.44 (-0.05)
Pernix Therapeutics Announces Pricing of Private Offering of $130 Million of 4.25% Convertible Senior Notes Due 2021
Business Wire - Fri Apr 17, 6:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX) (the "Company"
today announced that it has priced a private offering of $130 million aggregate principal amount of the Company's 4.25% Convertible Senior Notes due 2021, which will be sold only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" or institutional accredited investors as defined in Rule 501(a)(1), (2), (3) or (7) of Regulation D under the Securities Act. The size of the offering was increased from the previously announced aggregate principal amount of $120 million.
PTX: 7.44 (-0.05)
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HBNK: 22.21 (-0.41), EVOK: 6.43 (-0.08), ADXS: 22.18 (+0.10), PTX: 7.44 (-0.05), ANGI: 6.46 (+0.31), CDXS: 4.78 (+0.30), AKBA: 8.39 (+0.07), PCRX: 83.61 (-0.41), OTIC: 32.83 (unch)
Philip Morris and Netflix are big market movers
AP - Thu Apr 16, 3:22PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
PTX: 7.44 (-0.05), DAL: 46.53 (+0.30), ALU: 4.12 (+0.09), UL: 44.49 (-0.49), INTC: 32.70 (+0.27), MCP: 0.76 (-0.03), GOOG: 539.36 (+5.39), NOK: 8.00 (+0.16), NFLX: 557.68 (-2.76), PM: 83.69 (-0.36), ENPH: 13.38 (+0.03), GOOGL: 549.18 (+6.26), MTDR: 26.96 (+0.53), PCRX: 83.61 (-0.41), ALJ: 16.43 (+0.35), DK: 39.04 (+0.88), SWHC: 14.68 (-0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 11:45AM CDT
NPD: 2.87 (+0.25), INVE: 10.16 (-0.48), MNOV: 3.96 (-0.12), NHTC: 21.52 (+1.57), BSPM: 1.45 (-0.05), ANY: 3.33 (-0.16), TZOO: 13.06 (-0.02), FNRG: 3.11 (-0.86), RLJE: 1.06 (-0.01), PRTY: 20.65 (-0.22), PTX: 7.44 (-0.05), RCPI: 3.05 (+0.03), CHOP: 3.67 (-0.26), NVGN: 7.40 (-0.30), ETSY: 25.12 (-0.63), NFLX: 557.68 (-2.76), ENZN: 1.70 (+0.20), INUV: 2.32 (-0.05), GLF: 13.77 (-0.11), PCRX: 83.61 (-0.41)
Pernix Therapeutics (PTX) Stock Falls Today on Updated Sales Guidance
at The Street - Thu Apr 16, 11:27AM CDT
Shares of Pernix Therapeutics (PTX) plummeted in afternoon trading Thursday after the company updated its full-year 2015 guidance.
PTX: 7.44 (-0.05)
Pernix off 13% premarket on revised guidance and lower Treximet scrips
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:20AM CDT
PTX: 7.44 (-0.05)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:12AM CDT
NFLX: 557.68 (-2.76), PM: 83.69 (-0.36), INVE: 10.16 (-0.48), SNTA: 2.97 (+0.01), MNOV: 3.96 (-0.12), TZOO: 13.06 (-0.02), PNRA: 181.59 (-2.26), CLRX: 0.95 (unch), REN: 1.36 (-0.06), PTX: 7.44 (-0.05), CPLP: 9.48 (-0.17), NVGN: 7.40 (-0.30), MTDR: 26.96 (+0.53), PCRX: 83.61 (-0.41), SNDK: 68.48 (+0.56)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 4:35PM CDT
NFLX: 557.68 (-2.76), CJES: 14.02 (-0.23), SNTA: 2.97 (+0.01), PTX: 7.44 (-0.05), CPLP: 9.48 (-0.17), TCPI: 3.85 (-0.13), PKD: 4.10 (-0.04), SFM: 33.33 (-0.06), BCEI: 24.50 (-0.20), GSAT: 3.14 (-0.06)
Pernix Therapeutics initiates convertible debt offering
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 3:23PM CDT
PTX: 7.44 (-0.05)
Pernix Therapeutics Provides Business Update
Business Wire - Wed Apr 15, 3:01PM CDT
--- Q1 2015 Conference Call Scheduled for May 1, 2015 -
PTX: 7.44 (-0.05)
Pernix Therapeutics Announces Private Offering of $120 Million of Convertible Senior Notes Due 2021
Business Wire - Wed Apr 15, 3:00PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (the "Company" today announced that it has commenced a private offering of $120 million aggregate principal amount of the Company's Convertible Senior Notes due 2021, which will be offered and sold only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" or institutional accredited investors as defined in Rule 501(a)(1), (2), (3) or (7) of Regulation D under the Securities Act.
PTX: 7.44 (-0.05)
Pernix Therapeutics Announces Launch of Consent Solicitation for Its 12% Senior Secured Notes Due 2020
Business Wire - Mon Apr 13, 3:30PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX) (the "Company" today announced that it is seeking consents (the "Consent Solicitation" for proposed amendments to the indenture, dated August 19, 2014 (the "Indenture", that governs the Company's 12% Senior Secured Notes due 2020 (the "Notes".
PTX: 7.44 (-0.05)
Pernix Therapeutics Holdings (PTX) Is Today's Dead Cat Bounce Stock
at The Street - Wed Apr 22, 8:49AM CDT
Trade-Ideas LLC identified Pernix Therapeutics Holdings (PTX) as a "dead cat bounce" (down big yesterday but up big today) candidate
PTX: 7.44 (-0.05)
A Look at the Health of the HealthCare Sector: Complementary Research on Horizon Pharma, Enzon Pharmaceuticals, Momenta Pharmaceuticals, Athersys, and Pernix Therapeutics
PR Newswire - Tue Apr 21, 9:46AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENZN: 1.70 (+0.20), PTX: 7.44 (-0.05), HZNP: 30.96 (+0.10), ATHX: 1.34 (+0.01), MNTA: 18.62 (+0.56)
FDA grants pediatric exclusivity for Pernix's Treximet; patents extended into 2018
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 9:24AM CDT
PTX: 7.44 (-0.05)
Pernix Therapeutics prices issue of USD130m convertible senior notes
M2 - Mon Apr 20, 8:17AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NYSE
TX) said on Friday that it has priced its private offering of USD130m aggregate principal amount of 4.25% convertible senior notes due 2021. PTX: 7.44 (-0.05)
Pernix Therapeutics Inc. Obtains Six Months U.S. Pediatric Exclusivity for Treximet
Business Wire - Mon Apr 20, 6:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that Pediatric Exclusivity has been granted by the U.S Food and Drug Administration (FDA) for studies conducted on Treximet(R) (sumatriptan/naproxen sodium), effective April 16, 2015, under section 505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a). Based on this decision, an additional six months of U.S. market exclusivity will attach to the patents that are listed in FDA's Orange Book for Treximet, or until February 14, 2018. PTX: 7.44 (-0.05)
Pernix Therapeutics Inc. to Report First Quarter 2015 Financial Results
Business Wire - Fri Apr 17, 3:14PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, announced today that it will release its first quarter 2015 financial results on Friday, May 1, 2015, before the market opens. PTX: 7.44 (-0.05)
Pernix prices upsized convertible debt offering
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 6:23AM CDT
PTX: 7.44 (-0.05)
Pernix Therapeutics Announces Pricing of Private Offering of $130 Million of 4.25% Convertible Senior Notes Due 2021
Business Wire - Fri Apr 17, 6:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX) (the "Company" today announced that it has priced a private offering of $130 million aggregate principal amount of the Company's 4.25% Convertible Senior Notes due 2021, which will be sold only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" or institutional accredited investors as defined in Rule 501(a)(1), (2), (3) or (7) of Regulation D under the Securities Act. The size of the offering was increased from the previously announced aggregate principal amount of $120 million. PTX: 7.44 (-0.05)
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HBNK: 22.21 (-0.41), EVOK: 6.43 (-0.08), ADXS: 22.18 (+0.10), PTX: 7.44 (-0.05), ANGI: 6.46 (+0.31), CDXS: 4.78 (+0.30), AKBA: 8.39 (+0.07), PCRX: 83.61 (-0.41), OTIC: 32.83 (unch)
Philip Morris and Netflix are big market movers
AP - Thu Apr 16, 3:22PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
PTX: 7.44 (-0.05), DAL: 46.53 (+0.30), ALU: 4.12 (+0.09), UL: 44.49 (-0.49), INTC: 32.70 (+0.27), MCP: 0.76 (-0.03), GOOG: 539.36 (+5.39), NOK: 8.00 (+0.16), NFLX: 557.68 (-2.76), PM: 83.69 (-0.36), ENPH: 13.38 (+0.03), GOOGL: 549.18 (+6.26), MTDR: 26.96 (+0.53), PCRX: 83.61 (-0.41), ALJ: 16.43 (+0.35), DK: 39.04 (+0.88), SWHC: 14.68 (-0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 11:45AM CDT
NPD: 2.87 (+0.25), INVE: 10.16 (-0.48), MNOV: 3.96 (-0.12), NHTC: 21.52 (+1.57), BSPM: 1.45 (-0.05), ANY: 3.33 (-0.16), TZOO: 13.06 (-0.02), FNRG: 3.11 (-0.86), RLJE: 1.06 (-0.01), PRTY: 20.65 (-0.22), PTX: 7.44 (-0.05), RCPI: 3.05 (+0.03), CHOP: 3.67 (-0.26), NVGN: 7.40 (-0.30), ETSY: 25.12 (-0.63), NFLX: 557.68 (-2.76), ENZN: 1.70 (+0.20), INUV: 2.32 (-0.05), GLF: 13.77 (-0.11), PCRX: 83.61 (-0.41)
Pernix Therapeutics (PTX) Stock Falls Today on Updated Sales Guidance
at The Street - Thu Apr 16, 11:27AM CDT
Shares of Pernix Therapeutics (PTX) plummeted in afternoon trading Thursday after the company updated its full-year 2015 guidance.
PTX: 7.44 (-0.05)
Pernix off 13% premarket on revised guidance and lower Treximet scrips
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:20AM CDT
PTX: 7.44 (-0.05)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:12AM CDT
NFLX: 557.68 (-2.76), PM: 83.69 (-0.36), INVE: 10.16 (-0.48), SNTA: 2.97 (+0.01), MNOV: 3.96 (-0.12), TZOO: 13.06 (-0.02), PNRA: 181.59 (-2.26), CLRX: 0.95 (unch), REN: 1.36 (-0.06), PTX: 7.44 (-0.05), CPLP: 9.48 (-0.17), NVGN: 7.40 (-0.30), MTDR: 26.96 (+0.53), PCRX: 83.61 (-0.41), SNDK: 68.48 (+0.56)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 4:35PM CDT
NFLX: 557.68 (-2.76), CJES: 14.02 (-0.23), SNTA: 2.97 (+0.01), PTX: 7.44 (-0.05), CPLP: 9.48 (-0.17), TCPI: 3.85 (-0.13), PKD: 4.10 (-0.04), SFM: 33.33 (-0.06), BCEI: 24.50 (-0.20), GSAT: 3.14 (-0.06)
Pernix Therapeutics initiates convertible debt offering
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 3:23PM CDT
PTX: 7.44 (-0.05)
Pernix Therapeutics Provides Business Update
Business Wire - Wed Apr 15, 3:01PM CDT
--- Q1 2015 Conference Call Scheduled for May 1, 2015 -
PTX: 7.44 (-0.05)
Pernix Therapeutics Announces Private Offering of $120 Million of Convertible Senior Notes Due 2021
Business Wire - Wed Apr 15, 3:00PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (the "Company"
today announced that it has commenced a private offering of $120 million aggregate principal amount of the Company's Convertible Senior Notes due 2021, which will be offered and sold only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" or institutional accredited investors as defined in Rule 501(a)(1), (2), (3) or (7) of Regulation D under the Securities Act. PTX: 7.44 (-0.05)
Pernix Therapeutics Announces Launch of Consent Solicitation for Its 12% Senior Secured Notes Due 2020
Business Wire - Mon Apr 13, 3:30PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX) (the "Company" today announced that it is seeking consents (the "Consent Solicitation" for proposed amendments to the indenture, dated August 19, 2014 (the "Indenture", that governs the Company's 12% Senior Secured Notes due 2020 (the "Notes". PTX: 7.44 (-0.05)
